| Document |
Document Title |
|
WO/2024/094170A1 |
Disclosed are an inhibitor compound of ubiquitin-specific protease 1 and a use thereof. The inhibitor compound specifically relates to a compound represented by formula (I) or an enantiomer, a diastereomer, a racemate, a tautomer, a ster...
|
|
WO/2024/097948A1 |
Provided herein are compounds, including compounds of Formula (I) (e.g., compounds of Formula (I-a)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-c...
|
|
WO/2024/097953A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
|
WO/2024/096117A1 |
Provided are: a carbon dioxide absorbing/releasing liquid that has high carbon dioxide absorbing performance and high carbon dioxide releasing performance at low temperature, and that is less likely to degrade when absorbing and releasin...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/093956A1 |
The present invention relates to the technical field of medicines, in particular to a polycyclic poly(ADP-ribose) polymerase (PARP) selective inhibitor compound as represented by general formula (I), a pharmaceutically acceptable salt th...
|
|
WO/2024/094819A1 |
The present invention provides compounds of Formula (Ia) or (Ib) and methods of use thereof.
|
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
|
WO/2024/097897A1 |
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
|
|
WO/2024/097736A1 |
Disclosed are processes for preparing azolopyrimidine compounds (including etrumadenant), process intermediates useful for the preparation of azolopyrimidine compounds, and pharmaceutical compositions comprising the same. A particularly ...
|
|
WO/2024/096753A1 |
The present invention provides compounds of Formula (la) or (lb): and methods of use thereof.
|
|
WO/2024/095053A1 |
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers. T...
|
|
WO/2024/094190A1 |
The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune dis...
|
|
WO/2024/093412A1 |
A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cereb...
|
|
WO/2024/094816A1 |
The invention provides a compound of formula (I), or a pharmaceutically acceptable salt, ester or carbamate thereof, or a salt of such an ester or carbamate, wherein either: R1 is OH, and R2 is H; or R1 is H, and R2 is OH. The invention ...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2023/116835A9 |
Provided is a multi-protein degradation agent having an imide skeleton, which can degrade multiple proteins comprising c-Myc, GSPT1, CK1α and IKZF (1/2/3) proteins, and therefore can be used for treating diseases or disorders related th...
|
|
WO/2024/089159A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, pharmaceutical compositions comprising the compounds and methods for synthesising compounds according to formula I. This invention further...
|
|
WO/2024/088407A1 |
Disclosed are a nitrogen-containing fused ring compound as shown in formula (I), an intermediate thereof, a preparation method therefor and the use thereof. The compound has a DNA polymerase θ inhibitory activity, and can be used for tr...
|
|
WO/2024/089008A1 |
The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
|
|
WO/2024/087843A1 |
Disclosed are a chiral functionalized modified MOF adsorbent, the preparation thereof, and an application thereof in nicotine enantiomer resolution. The present invention introduces chiral small molecules into a secondary structural unit...
|
|
WO/2024/089190A1 |
There are disclosed compounds able to modulate and specifically inhibit the activity of Prune1 protein, pharmaceutical compositions containing them and the use thereof alone or in combination with chemotherapeutic agents in the preventio...
|
|
WO/2024/091542A1 |
The present disclosure relates to compounds of formula (I), which are capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of said compounds and methods of using said compound...
|
|
WO/2024/088069A1 |
Compounds of general formula (I) and formula (II) have good activity for inhibiting tumor growth and have good safety. Provided are preparation for a Kras inhibitor and a use thereof. Specifically, provided are compounds represented by f...
|
|
WO/2024/015948A3 |
The present disclosure relates to the use of substituted N-phenyluracils, such as those having a substituted alkyl ester side chain, or agrochemically acceptable salts thereof, for controlling or preventing weed growth in plant growth ar...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/091024A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2024/088282A1 |
The present invention provides a pyridazine compound as shown in formula (II), a preparation method therefor, and uses thereof. Also disclosed are uses of the compound of the present invention or the pharmaceutical composition thereof in...
|
|
WO/2024/092149A1 |
A new class of dimeric 2-aminoimidazole (2-AI) compounds that potentiate macrolide antibiotics against A. baumannii. A parent dimer lowers the MIC of clarithromycin (CLR) from 32 µg/mL to 1 µg/mL at a concentration of 7.5 µM (3.4 µg/...
|
|
WO/2024/088351A1 |
Disclosed herein are compounds or pharmaceutically acceptable salts thereof that are useful as inhibitors for activity of a BAF complex. Also disclosed are pharmaceutical compositions comprising such compounds, and methods of using such ...
|
|
WO/2024/089045A1 |
The present invention relates to a compound of formula (I) or its pharmaceutically acceptable salt. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) or its pharmaceutically acce...
|
|
WO/2024/091409A1 |
The present disclosure provides certain tetracyclic derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
|
|
WO/2024/087332A1 |
The present invention relates to the technical field of medicines, and provides a bifunctional compound used as a target protein degradation agent and a use thereof in target protein lysosomal degradation. The bifunctional compound compr...
|
|
WO/2024/092039A1 |
Described herein, in part, are compounds that mediate the degradation of cyclin-dependent kinase 2 (CDK2), and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2024/092255A2 |
The present invention concerns substituted N-(4-(piperidin-4-yl)phenyl)quinolin-4-amine and N-(4-(piperazin-l-yl)phenyl)quinolin-4-aminecompounds having the general Formula (I), below, and useful in the treatment of malaria, including Mu...
|
|
WO/2024/091538A1 |
The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/089668A1 |
The subject matter described herein is directed to somatostatin receptor activating compounds, methods of making the compounds, pharmaceutical compositions, and their use in the treatment of diseases associated with somatostatin receptors.
|
|
WO/2024/088377A1 |
Disclosed are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, X and Y are as defined in the present disclosure.
|
|
WO/2024/088991A1 |
The present invention relates to heterocyclic compounds of formula (I) capable of activating STING (Stimulator of Interferon Genes).
|
|
WO/2024/091541A1 |
The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
|
|
WO/2024/089006A1 |
The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
|
|
WO/2024/087977A1 |
The present invention relates to a phenylurea compound capable of targeting SHP2, and a preparation method therefor, the use thereof and a pharmaceutical composition thereof. The compound is as represented by formula (I). The present inv...
|
|
WO/2024/088323A1 |
This disclosure provides compounds containing 6- (pyrimidin-4-yl) quinoline structure, the use thereof for selectively inhibiting the activity of CDK4, and pharmaceutical compositions comprising the compounds as treatment of various dise...
|
|
WO/2024/090369A1 |
This compound is a compound represented by general formula (I). (In the formula, X represents a hydrogen atom, an optionally substituted cyclic group in which the number of carbon atoms in the cyclic structure is 2-20, an optionally subs...
|
|
WO/2024/085695A1 |
The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
|
|
WO/2024/083182A1 |
The present invention relates to a method for preparing a phosphonyl derivative, and specifically relates to a method for preparing the compound as represented by formula (A) and intermediates thereof. The method is mild in reaction cond...
|
|
WO/2024/084394A1 |
Compounds and methods are provided for facilitating delivery of an oligonucleotide, for example, into a nucleus and/or cytosol of a cell.
|
|
WO/2024/083183A1 |
Provided in the present invention are a pharmaceutically acceptable salt of a compound as represented by formula (I) or a stereoisomer thereof, a solvate and/or a crystal form thereof, a preparation method therefor, a pharmaceutical comp...
|
